Engineered γδ T-APC Development Services

The human γδ T cell is a small group of T lymphocytes carrying a distinctive γδ cell receptor, which has an enhanced antigen-presenting function after activation. With abundant experience in cell bioengineering during the past decades, Creative Biolabs has developed an advanced technology platform to provide rapid and high-quality γδ T-APC development services for clients throughout the world.

Antigen Recognition by γδ T cell

T cell receptor (TCR) expressed on the surface T lymphocyte is a protein complex that is mainly responsible for antigen recognition. Human T cells are divided into two subsets according to the peptide chains that make up TCR, one is αβ T cell with α and β chains TCR and the other is γδ T cell with γ and δ chains TCR.

Fig.1 Structure of human αβ TCR and γδ TCR. (Morath, 2020)

Both the αβ T cell and γδ T cell can recognize a variety of antigens. Commonly αβ T cells recognize peptide antigens presented on the major histocompatibility complex (MHC) on the surface of antigen-presenting cells (APCs), among which CD4+ αβ T cells recognize peptides loaded on MHC class II molecule, whereas CD8+ αβ T cells bind to antigens on MHC class I molecule. Differently and importantly, γδ T cells can recognize a wide range of antigens in an MHC unrestricted manner without antigen processing. Activated γδ T cells can serve as a professional APC, recognizing and reacting with non-peptide antigens, soluble proteins, lipid antigens, MHC and non-MHC loaded antigens, etc.

Engineered γδ T-APC: a New Approach for γδ T Therapy

It has been demonstrated that stimulating γδ T cells with phosphoantigens led to rapid or increased expression of antigen-presenting related markers on the surface of γδ T cells, such as MHC I, MHC II, co-stimulatory molecules, and adhesion receptors.These markers endow γδ T cells with APC-like functions that directly and professionally recognize and process antigens, as well as cytotoxicity through MHC I pathway.

Fig.2 Antigen processing and presentation in γδ T-APCs. (Moser, 2011)

Therefore, by stimulating with phosphoantigens or related ligands, γδ T cells with enhanced antigen-presenting functions (γδ T-APC) can be obtained in vitro, which is similar to and superior to the widely used monocyte-derived dendritic cells, exhibiting great potential for immunotherapy as a cellular vaccine. Based on the γδ T cell generation and development methods, it is not difficult to harvest and expand γδ T-APC on a large scale for clinical applications.

Fig.3 In vitro generation of γδ T-APCs for use in immunotherapy. (Moser, 2011)

Engineered γδ T-APC Development Services in Creative Biolabs

Since the discovery in 1984, γδ T cell therapy has drawn much concentration of researchers in terms of human disease immunotherapy. Creative Biolabs, a leading biotechnology company dedicated to novel therapy discovery, has been recognized as an excellent supplier of immunotherapy. Based on enriched experience, we provide custom engineered γδ T-APC development services for different applications.

For details, please directly contact us, we will offer you the most tailored solutions and support as soon as possible.

References

1. Morath, A., Schamel, W.W. αβ and γδ T cell receptors: Similar but different. Journal of Leukocyte Biology. 2020, 107(6): 1045-1055.
2. Moser, B., Eberl, M. γδ T-APCs: a novel tool for immunotherapy? Cellular and Molecular Life Sciences. 2011, 68(14): 2443-2452.